Palleon to present HLX79 and rituximab combination data at ACR Convergence 2026
Palleon Pharmaceuticals will present interim Phase 2 results for HLX79 plus a rituximab biosimilar in membranous nephropathy. A publicly available abstract reports 17 remissions among 26 patients, although the blinded analysis includes patients receiving rituximab without HLX79.
